Cocrystal Pharma (COCP) Co-CEO and CFO James Martin - C-Suite Interview Series

Описание: Recorded November 16, 2023. Noble Capital Markets Senior Research Analyst Robert LeBoyer sits down with Cocrystal Pharma Co-CEO and CFO James Martin for this exclusive interview. Topics covered include:
What sets Cocrystal apart from its peers
Progress update on Influenza A clinical development
Advantages of a human challenge study over the standard clinical trial
Market opportunity for Cocrystal’s Influenza anti-viral
Progress on Phase 1 trail for dual antiviral candidate for coronavirus and norovirus
What to expect from Cocrystal in the coming months

Research, News, and Market Data on Cocrystal Pharma: https://channelchek.com/company/cocp

About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2) noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.